SciSparc (SPRC)announced the publication of a Japanese divisional patent. The patent application introduces a novel pharmaceutical combination of paracetamol and palmitoylethanolamide that may enhance pain relief and fever relief with lower doses and fewer side effects compared to paracetamol monotherapy, with potential for safer and more effective treatment for millions worldwide.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRC:
- SciSparc Ltd. Announces Annual General Meeting for June 2025
- SciSparc and Clearmind Secure European Patent for Cocaine Addiction Therapy
- SciSparc, Clearmind announce publication of European patent
- Clearmind Medicine announces publication of European patent application
- Biotech Alert: Searches spiking for these stocks today